Digestive System Diseases: Causes, Symptoms, and Prevention
The digestive system represents an essential anatomo-physiological complex for the body’s homeostasis, having fundamental roles in the enzymatic degradation of macronutrients, nutrient absorption, and excretion of residual metabolites. This complex system integrates specialized structures, including the esophagus, stomach, small and large intestine, liver, exocrine pancreas, and gallbladder, each contributing to digestion through specific biochemical and motor mechanisms. Dysfunctions at any of these components can lead to digestive pathology variable in severity, from benign functional disorders, such as dyspepsia or irritable bowel syndrome, to severe organic conditions, such as inflammatory bowel diseases, gastrointestinal neoplasms, or liver failure. In this article, the etiology, clinical manifestations, and prophylactic strategies of digestive disorders will be analyzed, offering a medical perspective on optimizing gastrointestinal health.
What are digestive system diseases?
Photo source: Shutterstock.com
Digestive system pathology encompasses a complex set of conditions with variable etiology, including infectious, inflammatory, autoimmune, metabolic, neoplastic, and functional factors, which compromise the physiological processes of digestion, absorption, and elimination of residual metabolites. These disorders can affect any segment of the digestive tract, from the esophagus to the rectum, as well as accessory organs, including the liver, exocrine pancreas, and gallbladder, each having an essential role in gastrointestinal homeostasis.
The pathophysiology of these conditions involves dysfunctions of motor, secretory, enzymatic, and immunological mechanisms, which can generate varied clinical manifestations, from functional dyspepsia, gastroesophageal reflux, and intestinal transit disorders, to malabsorption syndromes, digestive bleeding, or liver failure. For instance, irritable bowel syndrome is a functional pathology characterized by dysmotility and visceral hypersensitivity, without structural lesions, while inflammatory bowel disease (Crohn’s disease and ulcerative colitis) involves a chronic immunomediated inflammatory process, with segmental or continuous histological involvement of the intestinal mucosa.
In the realm of neoplastic disorders, colorectal cancer represents one of the leading causes of cancer mortality worldwide, favored by genetic predisposition, chronic inflammation, and modifiable risk factors such as a high-protein diet and sedentary lifestyle. Hepatobiliary pathologies, such as non-alcoholic steatohepatitis or liver cirrhosis, involve disturbances in lipid metabolism and progressive fibrosis, which can progress to terminal liver failure or hepatocellular carcinoma.
The impact of digestive diseases on health and available treatments
According to epidemiological data published in “Gastroenterology,” digestive diseases constitute a major cause of morbidity and mortality, having a significant impact on patients’ quality of life. The management of these conditions involves differential diagnosis based on imaging investigations (upper gastrointestinal endoscopy, colonoscopy, liver elastography) and serum biomarkers (transaminases, fecal calprotectin, CA 19-9), in order to implement a personalized therapeutic approach, which may include pharmacological, dietary, or surgical interventions.
[cta_produs style=”style_1″ product=”432555″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/03/Ce-reprezinta-bolile-sistemului-digestiv_-produs-HERO.jpg”]
Given the complexity of gastrointestinal pathologies and their impact on general health, effective therapeutic strategies must include both established medical treatments and complementary natural solutions aimed at supporting digestive balance and optimal gastrointestinal function. In this context, natural supplements with proven beneficial effects can be a valuable adjuvant in managing common conditions such as irritable bowel syndrome, functional dyspepsia, intestinal dysbiosis, or transit disorders.
Gastrointestinal Health Package, composed of *Aloe Vera Gel*, *Premium Colon Cleanse Formula*, and *Premium Probiotic-Prebiotic Vegan*, offers integrated support for maintaining digestive homeostasis through multiple mechanisms. Aloe Vera Gel, formulated with a high content of bioactive polysaccharides and anti-inflammatory compounds, protects the gastric mucosa, promoting epithelial cell regeneration and reducing discomfort associated with hyperacidity and gastritis. Additionally, its prebiotic compounds stimulate beneficial microbiota, contributing to the balance of the intestinal flora.
Premium Colon Cleanse Formula for intestinal health
Premium Colon Cleanse Formula, based on ingredients such as psyllium, chlorella, flaxseed, and artichoke, facilitates colon detoxification, promotes intestinal motility, and aids in the elimination of waste, preventing constipation and toxin accumulation in the lower digestive tract. This formula is particularly useful in managing transit disorders and dysfunctions associated with irritable bowel syndrome.
Premium Probiotic-Prebiotic Vegan, with its 7 strains of beneficial bacteria, optimizes the composition of intestinal microbiota, reducing dysbiosis associated with prolonged antibiotic use, oxidative stress, and chronic intestinal inflammation. For example, probiotics are essential for improving digestion and nutrient absorption, preventing bloating, and strengthening mucosal immunity.
By including these supplements in the daily regimen, natural and effective support for gastrointestinal health can be achieved.
Classification of gastrointestinal disorders, disorders, and digestive system diseases
The nosological classification of digestive system diseases is based on pathophysiological, anatomoclinical, and etiopathogenetic criteria, facilitating a differentiated diagnostic and therapeutic approach. These pathologies can be delineated into functional disorders and organic/structural disorders, each having distinct clinical, imaging, and histopathological particularities.
Functional pathologies are characterized by alterations in gastrointestinal motility, visceral hypersensitivity, and neuroenteric dysfunctions, without morphological abnormalities detectable by conventional imaging investigations or histology. A paradigm example is irritable bowel syndrome (IBS), an entity defined by the Rome IV criteria, manifested by recurrent abdominal pain associated with intestinal transit dysfunction (constipation, diarrhea, or alternation between the two), in the absence of organic lesions. Other functional entities include functional dyspepsia, gastric emptying disorders, and biliary dyskinesia.
In contrast, structural disorders are characterized by histological, inflammatory, degenerative, or proliferative changes, which cause significant digestive dysfunction. These include peptic ulcer (associated with hyperchlorhydria, *Helicobacter pylori* infection, or NSAID use), colonic diverticulosis (caused by intraluminal pressure abnormalities and intestinal wall fragility), inflammatory bowel disease (IBD) – which includes Crohn’s disease and ulcerative colitis, immunomediated pathologies with transmural or exclusively mucosal involvement – and gastrointestinal neoplasms, such as colorectal adenocarcinoma or gastric cancer, pathologies frequently associated with genetic factors and oncogenic exposures (diet, *H. pylori* infection, hereditary syndromes like Lynch or familial adenomatous polyposis).
From a topographic point of view, digestive diseases are grouped into:
- Diseases of the upper digestive tract: peptic esophagitis, gastroesophageal reflux disease (GERD), erosive gastritis, gastric and duodenal ulcer.
- Diseases of the lower digestive tract: Crohn’s disease, ulcerative colitis, colonic diverticulosis, intestinal tumors.
- Hepatobiliary and pancreatic pathologies: non-alcoholic steatohepatitis (NASH), liver cirrhosis of various etiologies, cholelithiasis, acute and chronic pancreatitis, pancreatic adenocarcinoma.
According to epidemiological data provided by the World Health Organization and reference publications in *Gastroenterology*, digestive pathologies constitute a major determinant of global morbidity, with an increasing prevalence in the context of lifestyle Westernization and exposure to modifiable risk factors. Optimizing primary and secondary prevention strategies, early diagnosis through serological biomarkers and advanced imaging (magnification endoscopy, liver elastography, molecular testing of precancerous lesions), and the development of personalized therapies are essential for reducing the burden of these conditions on healthcare systems.
The most common diseases of the stomach and digestive system
Pathology of the upper and lower gastrointestinal tract encompasses a series of conditions with multifactorial etiology, involving inflammatory, infectious, autoimmune, and neurofunctional mechanisms, which can compromise the integrity of the mucosa and the functionality of digestive organs. Thus, knowing frequent pathological entities allows for early recognition of symptoms and the implementation of an adequate therapeutic approach, preventing associated complications.
One of the most prevalent conditions is *gastroesophageal reflux disease (GERD)*, characterized by pathological reflux of acidic gastric content into the esophagus, secondary to lower esophageal sphincter dysfunction and esophageal motility disorders. Clinical manifestations include heartburn, acid regurgitation, and, in severe cases, odynophagia, chronic cough, or endoscopically visible esophageal erosions. In complicated forms, GERD can progress to erosive esophagitis, esophageal strictures, or Barrett’s esophagus, a precancerous lesion associated with esophageal adenocarcinoma.
*Gastritis*, inflammation of the gastric mucosa, can have an infectious etiology (associated with *Helicobacter pylori*), toxic (chronic alcohol consumption), medicinal (NSAIDs, corticosteroids), or autoimmune (atrophic gastritis) cause. It manifests with epigastric pain, dyspepsia, nausea, and, in severe cases, hematemesis or melena, suggesting upper gastrointestinal bleeding.
Diagnosis and treatment of peptic ulcer
*Peptic ulcer*, defined in the literature as a condition involving a loss of substance in the gastric or duodenal mucosa, is frequently associated with *H. pylori* infection or chemical aggression caused by ulcerogenic drugs. Clinically, patients present with epigastric pain with meal periodicity (pain exacerbated postprandially in gastric ulcer and relieved by ingestion in duodenal ulcer), as well as digestive discomfort. Major complications include gastrointestinal bleeding, perforation, and pyloric stenosis, requiring emergency medical intervention.
In the lower digestive segment, *irritable bowel syndrome (IBS)* is a functional condition defined by the Rome IV criteria, characterized by recurrent abdominal pain, bloating, and changes in bowel habits, in the absence of organic lesions. It is associated with visceral hypersensitivity, altered intestinal microbiota, and gut-brain axis dysfunctions.
In contrast, *inflammatory bowel disease (IBD)*, which includes Crohn’s disease and ulcerative colitis, represents an immunomediated pathological spectrum, characterized by chronic transmural inflammation (in Crohn’s disease) or limited to the colonic mucosa (in ulcerative colitis). Clinical manifestations can be recognized by chronic diarrhea (frequently bloody in ulcerative colitis), abdominal pain, weight loss, and extraintestinal manifestations (arthritis, uveitis, primary sclerosing cholangitis). The disease’s progression can lead to intestinal strictures, abscesses, fistulas, or malignant degeneration, requiring immunomodulatory, biological, or, in severe cases, surgical treatment.
Risk factors and causes of digestive problems and digestive diseases
Photo source: Shutterstock.com
Identifying and understanding the risk factors involved in the etiopathogenesis of digestive disorders are essential for the primary and secondary prevention of these pathologies. Predisposing factors can be classified into nutritional, behavioral, infectious, and iatrogenic factors, each having different implications for gastrointestinal function and intestinal microbiota homeostasis.
Firstly, *nutritional factors* play a determinant role in digestive health, influencing inflammatory processes, intestinal motility, and microbial balance. A hypercaloric diet, rich in saturated fats, refined sugars, and ultra-processed foods, promotes systemic inflammation, increased intestinal permeability, and dysbiosis, mechanisms involved in the pathogenesis of inflammatory bowel diseases, irritable bowel syndrome, and colorectal carcinogenesis. Deficiency in dietary fiber, from fruits, vegetables, and whole grains, compromises intestinal transit, favoring chronic constipation and colonic fermentation disorders, elements correlated with colonic diverticulosis and functional colopathies.
*Behavioral factors* directly influence gastrointestinal motility and the neuroendocrine response of the digestive tract. Sedentary lifestyle leads to intestinal hypomotility, favoring colonic stasis and transit disorders. Chronic stress, through the hypothalamic-pituitary-adrenal axis, exacerbates motility dysfunctions and visceral hypersensitivity, worsening functional pathologies such as irritable bowel syndrome. Chronic alcohol consumption causes direct toxic effects on hepatocytes, favoring alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Smoking increases the risk of peptic ulcer by stimulating gastric acid secretion and affecting the protective mechanisms of the gastrointestinal mucosa.
Impact of infections on the digestive system
*Infectious factors* have a major impact on digestive integrity and function. *Helicobacter pylori* infection is a primary cause of chronic atrophic gastritis, peptic ulcer, and gastric adenocarcinoma, through inflammatory mechanisms and histopathological alterations of the gastric mucosa. Viral infections, such as hepatitis B and C viruses, are involved in the pathogenesis of chronic active hepatitis, progressively evolving towards liver fibrosis, compensated or decompensated cirrhosis, and hepatocellular carcinoma.
Last but not least, *iatrogenic factors*, especially the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are frequently associated with gastric and duodenal lesions, having an ulcerogenic effect by inhibiting the synthesis of protective prostaglandins of the mucosa. Prolonged antibiotic therapy can disrupt the intestinal flora, favoring dysbiosis and opportunistic infections, such as pseudomembranous colitis caused by *Clostridioides difficile*.
In the context of the increasing incidence of digestive diseases globally, prophylactic approaches, including lifestyle modifications, dietary optimization, and active screening for digestive infections, are essential for reducing the impact of these conditions on public health.
Symptoms and warning signs of stomach and digestive diseases
Early identification of symptoms and warning signs associated with digestive disorders is essential for differential diagnosis and the initiation of adequate therapeutic management. As previously mentioned, digestive symptomatology can be nonspecific, but certain clinical characteristics provide important clues about the underlying etiology.
*Abdominal pain* is one of the most frequent gastrointestinal symptoms and can have a variable character depending on the underlying pathology. For example, epigastric pain with a burning character, exacerbated postprandially, suggests gastroesophageal reflux disease (GERD) or gastric ulcer. Nocturnal epigastric pain relieved by food intake is indicative of duodenal ulcer. Conversely, periumbilical pain that migrates to the right iliac fossa requires exclusion of acute appendicitis, and colicky flank pain radiating to the lower back is characteristic of ureteral lithiasis, which can mimic digestive pathology.
*Intestinal transit disorders* are a key element in the evaluation of gastrointestinal disorders. Chronic constipation, defined by infrequent stools (<3/week) and difficult evacuation, is frequently associated with irritable bowel syndrome (IBS) but can also indicate mechanical obstruction (tumors, intestinal strictures). Chronic diarrhea, accompanied by watery or bloody stools, may indicate inflammatory bowel disease (IBD), intestinal malabsorption (celiac disease), or pseudomembranous colitis secondary to *Clostridioides difficile* infection.
Signs and causes of nausea and vomiting
Nausea and vomiting can have multiple gastrointestinal and extragastrointestinal causes. Vomiting of digested blood (hematemesis, “coffee grounds” appearance) is an alarming sign of upper gastrointestinal bleeding, possibly secondary to a complicated gastric ulcer, esophageal varices, or severe erosive gastritis. Bilious vomiting suggests duodenal obstruction, and late vomiting of food, several hours after ingestion, may indicate gastric stasis secondary to gastroparesis or pyloric stenosis.
*Abdominal bloating* and *excessive flatulence* are frequently associated with intestinal dysbiosis, food intolerances (lactose, fructose, gluten), or small intestinal bacterial overgrowth (SIBO). These manifestations can also occur in irritable bowel syndrome, being exacerbated by the consumption of fermentable foods from the FODMAPs group (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols).
Certain manifestations require emergency medical evaluation due to the risk of severe complications:
- Hematochezia (bright red blood in stool) or melena (black, tarry, sticky stool) → suggests lower gastrointestinal bleeding (hemorrhagic diverticulum, colorectal cancer) or upper gastrointestinal bleeding (bleeding ulcer, esophageal varices).
- Unintended weight loss and anorexia → raise suspicion of digestive malignancy (gastric, colorectal, pancreatic carcinoma) or severe malabsorption (celiac disease, exocrine pancreatic insufficiency).
- Progressive dysphagia (difficulty swallowing) → may indicate esophageal stenosis post-complicated GERD or esophageal neoplasm.
- Sclero-cutaneous jaundice (yellowing of the skin and mucous membranes) → suggests severe hepatobiliary-pancreatic pathology (acute hepatitis, obstructive cholestasis, pancreatic carcinoma).
- Severe acute abdominal pain with sudden onset → may indicate gastrointestinal perforation, acute pancreatitis, or mesenteric ischemia, medical-surgical emergencies requiring prompt evaluation.
Therefore, complementary investigations, including upper and lower gastrointestinal endoscopy, abdominal ultrasound, abdominal CT, and serological tests (fecal calprotectin, liver and pancreatic function tests, tumor markers CA 19-9, CEA), are essential for the etiological diagnosis and risk stratification of gastrointestinal pathologies.
Diagnosis of digestive system diseases
The diagnosis of digestive system diseases requires a complex approach, based on detailed history taking, clinical examination, and appropriate paraclinical investigations, essential for correctly identifying the underlying conditions of stomach and gastrointestinal problems. Thus, a thorough evaluation is crucial for establishing effective treatment and preventing complications associated with gastrointestinal issues.
The diagnostic process begins with history taking, during which the physician investigates the nature and severity of symptoms, their duration, triggering and alleviating factors, personal and family medical history, as well as the patient’s lifestyle. Physical examination can provide important clinical clues, such as abdominal tenderness, sclero-cutaneous jaundice, ascites, or palpable masses, signs that may indicate stomach problems, hepatobiliary pathologies, inflammatory bowel diseases, or tumor processes.
Laboratory investigations in the diagnosis of gastrointestinal disorders
Laboratory investigations play an essential role in diagnosing gastrointestinal problems, providing information about systemic inflammation, occult bleeding, liver and pancreatic function, or the presence of markers specific to certain conditions such as celiac disease and viral hepatitis. A complete blood count can indicate iron deficiency anemia secondary to gastrointestinal bleeding, while C-reactive protein and fecal calprotectin are useful in evaluating inflammatory bowel disease. Liver tests (AST, ALT, GGT, bilirubin, alkaline phosphatase) detect hepatobiliary dysfunction, while elevated serum amylase and lipase levels are indicative of acute pancreatitis. Additionally, serological tests for *Helicobacter pylori* are essential in diagnosing chronic gastritis and peptic ulcer, two of the most common stomach problems. Stool analysis is also an important component of diagnosis, as it can identify the presence of occult blood, parasitic, or bacterial infections, or specific inflammatory markers.
Furthermore, imaging methods provide a detailed visualization of digestive structures and are essential in detecting organic pathologies. Abdominal ultrasound is used to evaluate solid organs and detect gallstones, while computed tomography (CT) and magnetic resonance imaging (MRI) are essential in diagnosing tumors, pancreatitis, and inflammatory bowel disease complications. Endoscopic procedures, such as upper gastrointestinal endoscopy and colonoscopy, allow for direct visualization of the digestive tract mucosa and are used to identify erosive, ulcerative, or neoplastic lesions and to collect biopsies for histopathological examination.
Summarizing the information presented above, such techniques are indispensable in diagnosing complex gastrointestinal problems, offering both exploratory possibilities and minimally invasive therapeutic options, such as colonic polyp excision or control of gastrointestinal bleeding. Early detection of signs and symptoms, combined with the appropriate use of these diagnostic methods, is key to effective management of digestive disorders and stomach problems, contributing to reduced morbidity and improved quality of life for patients.
Treatment of digestive system diseases + How to choose it based on how a digestive system disease manifests
Photo source: Shutterstock.com
The treatment of digestive system diseases is determined by the etiology, severity, and evolution of the condition, involving therapeutic strategies aimed at alleviating symptoms, preventing complications, and improving prognosis. Instead, the management of gastrointestinal pathologies is based on an individualized approach, adapted according to comorbidities, therapeutic response, and prognostic factors. Depending on the complexity of the case, treatment may require a multidisciplinary team, including gastroenterologists, surgeons, nutritionists, hepatologists, and infectious disease specialists.
In *inflammatory bowel diseases* (Crohn’s disease and ulcerative colitis), the treatment aims to control inflammation, induce and maintain remission, and prevent recurrences. Therapeutic strategies include aminosalicylates (mesalazine, sulfasalazine) in mild forms, corticosteroids for severe flares, immunomodulators (azathioprine, methotrexate) for refractory forms, and biological agents (anti-TNF monoclonal antibodies – infliximab, adalimumab, vedolizumab) in severe or corticosteroid-dependent cases. In complicated forms (fibrous strictures, abscesses, fistulas), surgical intervention (segmental colectomy, ileocecal resection) may become necessary.
When referring to *gastroesophageal reflux disease (GERD)*, initial treatment includes hygienic-dietary measures (avoiding acidic foods, small and frequent meals, elevating the head of the bed), and drug therapy consists of proton pump inhibitors (omeprazole, pantoprazole), H2 receptor antagonists (ranitidine, famotidine), and prokinetics (domperidone, metoclopramide). In refractory or complicated forms (Barrett’s esophagus, esophageal strictures), Nissen fundoplication can be a surgical option.
Treatment of irritable bowel syndrome (IBS)
*Irritable bowel syndrome (IBS)* requires a multidimensional approach, including dietary modifications (FODMAPs diet, soluble fiber supplementation), symptomatic pharmacological therapy (antispasmodics – mebeverine, drotaverine; prokinetics – itopride, trimebutine; antidiarrheal agents – loperamide, or osmotic laxatives – lactulose, macrogol, in constipation-predominant forms).
In liver diseases, therapy varies depending on the etiology. Viral hepatitis (B and C) require antiviral treatment. This is based on nucleoside/nucleotide analogs (entecavir, tenofovir) for hepatitis B. For hepatitis C, direct-acting antivirals (sofosbuvir, ledipasvir) are used. In non-alcoholic steatohepatitis (NASH), interventions aim at weight loss. Control insulin resistance. Reduce oxidative stress. Metformin, vitamin E, or pioglitazone are used. Decompensated liver cirrhosis requires diuretic therapy (spironolactone, furosemide) for ascites. Non-selective beta-blockers (propranolol, carvedilol) prevent variceal bleeding. Liver transplantation is performed in terminal stages.
The therapeutic approach is always personalized. Disease severity is taken into account. Response to previous therapies is analyzed. Progression to severe complications is prevented. The development of biological and personalized therapies is important. These are important directions in gastroenterology. They offer effective solutions for patients with conditions refractory to conventional treatments.
Prevention of digestive system diseases
Prevention of digestive system diseases requires a multidimensional strategy. This strategy integrates nutrition optimization. It also includes maintaining an active lifestyle. Furthermore, it requires avoiding modifiable risk factors.
Firstly, a balanced diet plays a central role. It helps maintain gastrointestinal homeostasis. It supports enzymatic functionality. It aids intestinal motility. It maintains microbial balance. Increased consumption of soluble and insoluble dietary fiber is beneficial. These come from vegetables, fruits, whole grains, and legumes. They facilitate intestinal transit. They reduce the risk of constipation. They help with colonic diverticulosis. They prevent colorectal cancer. Adequate hydration is important. It is achieved through sufficient water intake. It contributes to maintaining normal stool consistency. It prevents colonic stasis. Limiting ultra-processed foods is essential. These are rich in saturated fats. They contain refined sugars and food additives. Limiting them helps prevent systemic inflammation. It prevents intestinal dysbiosis. These factors are involved in the pathogenesis of inflammatory bowel diseases. They are also involved in irritable bowel syndrome.
Regular physical activity has direct benefits on gastrointestinal function. It stimulates peristalsis. It prevents intestinal motor dysfunctions. Moderate physical exercise contributes to reducing the risk of chronic constipation. It improves abdominal discomfort associated with irritable bowel syndrome. It decreases the incidence of gastroesophageal reflux disease. This happens by reducing intra-abdominal pressure. Additionally, physical activity optimizes liver metabolism. It contributes to the prevention of non-alcoholic steatohepatitis (NASH). This is an emerging liver pathology. It is correlated with obesity and metabolic syndrome.
Effective stress management is another crucial element. It helps maintain digestive health. The neuroendocrine response of the hypothalamic-pituitary-adrenal axis can influence gastrointestinal motility. It can also affect intestinal permeability. It is involved in the pathophysiology of functional disorders. These include irritable bowel syndrome and functional dyspepsia.
Stress management and its impact on digestive health
Avoiding modifiable risk factors is essential for the primary prevention of digestive diseases. Quitting smoking reduces the incidence of peptic ulcer. It also reduces the incidence of esophageal and gastric neoplasia. Limiting alcohol consumption protects against alcoholic hepatopathies. It also protects against chronic pancreatitis. Furthermore, it protects against hepatocellular carcinoma. Prudent use of non-steroidal anti-inflammatory drugs (NSAIDs) is important. It helps prevent erosive gastritis and complicated peptic ulcer. This is especially true for patients with associated risk factors. These factors include Helicobacter pylori and a history of gastrointestinal bleeding.
Adequate personal and food hygiene prevents acute gastrointestinal infections. It prevents contamination with pathogenic bacteria. These include Salmonella, Campylobacter, and enterotoxigenic Escherichia coli. It also prevents intestinal parasitic infections. Proper hand washing is necessary. Adequate thermal processing of food is important. Avoiding consumption of insufficiently cooked products is important. These are essential measures for reducing the transmission of gastrointestinal pathogens.
Importance of screening and monitoring for early detection of digestive disorders
Regular screening is fundamental. It is especially important for colorectal cancer. It helps in the early detection of precancerous lesions. It allows for the initiation of curative treatment. Fecal occult blood testing is necessary. Colonoscopy in patients with a family history of digestive neoplasms is important. Monitoring tumor markers is essential. These include CEA and CA 19-9. These are essential components of secondary prevention strategy. In patients with chronic liver disease, periodic evaluations are necessary. These are done through liver elastography. Alpha-fetoprotein (AFP) measurement is important. Thus, malignant transformations are detected early.
In other words, adopting a balanced lifestyle is essential. A healthy lifestyle is combined with optimal nutrition. Regular physical activity is important. Stress reduction is necessary. Periodic screening is useful. These are the fundamental pillars of digestive disease prevention. They help maintain long-term gastrointestinal health.
In conclusion, caring for the digestive system is essential for overall health. By adopting healthy eating habits, maintaining an active lifestyle, and undergoing regular medical check-ups, the incidence of these pathologies can be significantly reduced.
References:
1. Peery AF, Crockett SD, Murphy CC, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019;156(1):254-272.e11. DOI: 10.1053/j.gastro.2018.08.063;
2. World Health Organization. Digestive Diseases. https://www.who.int/health-topics/digestive-diseases;
3. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561-581. DOI: 10.1016/S2468-1253(20)30117-5;
4. Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966-974. DOI: 10.1136/gutjnl-2016-313425;
5. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. DOI: 10.14309/ajg.0000000000001036;
6. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328. DOI: 10.1038/ajg.2012.444;
7. Spechler SJ, Katz PO, Scheiman JM, Castell DO. Gastroesophageal Reflux Disease: A Systematic Review. JAMA. 2015;314(23):2536-2543. DOI: 10.1001/jama.2015.16658.
Photo source: Shutterstock.com